Back to search

University of British Columbia

Polycationic inhibitors to target prothrombotic nucleic acids in vitro and in mouse models

Abstract

dc:description

Thrombosis is a common pathology that underpins ischemic heart disease, ischemic stroke, and venous thromboembolism and has been linked to sepsis and cancer. Polyanionic molecules such as polyphosphates, cell-free DNA, Neutrophil Extracellular Traps (NETs), and extracellular RNA have been shown to be the mediators of thrombosis. NETs are released from neutrophils when activated by microbial or inflammatory stimuli. These web-like structures are composed of cell-free DNA, histones, and antimicrobial proteins. They have been shown to trap and kill microorganisms, playing a critical role in host defense. The presence of NETs has been observed in sepsis and is shown to promote Disseminated Intravascular Coagulation (DIC) and multiorgan failure. This thesis presents a strategy for inhibiting nucleic acid-based mediators of thrombosis with Polycationic Nucleic Acid Binding Inhibitors (PNBIs). The general architecture of these PNBIs is similar to the Universal Heparin Reversal Agent (UHRA) class of molecules previously reported from our lab. They have a core of hyperbranched polyglycerol (HPG) with cationic binding groups (R) and a brush layer of methoxy polyethylene glycol (mPEG) to protect the R groups from non-specific interactions. We screened a library of such polycationic compounds developed in our lab with different R group types, R group numbers, and molecular weights of HPG core and identified effective candidates that target polyanionic nucleic acids and reverse their procoagulant potential in vitro. We also showed that lead PNBIs could reverse the altered clot properties caused by nucleic acids. Next, we demonstrated the inhibition of NET-associated immunothrombosis by PNBIs in the murine Cecal Ligation and Puncture (CLP) polymicrobial sepsis model. In addition to promoting thrombosis, NETs have been shown to increase hyperinflammation in sepsis. We showed that PNBIs could reduce the cytokine storm and the elevated coagulation parameters in this model while remaining well tolerated in mice. Besides demonstrating the inhibition of nucleic acids in both in vitro and in vivo, this work also provides new insights into the mechanism of coagulation activation by nucleic acids. The findings described in this thesis may pave the way for developing non-toxic molecules that target nucleic acids as new antithrombotic therapy.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pathology and Laboratory Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Vappala, Sreeparna
Contributors dc:contributor
  • Kizhakkedathu, Jayachandran N.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/83630

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Vappala, Sreeparna. Polycationic inhibitors to target prothrombotic nucleic acids in vitro and in mouse models. doctoral thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/83630